Study of susceptibility to vancomycin from clinical isolates of Staphylococcus aureus

Vancomycin has been considered for over 40 years as the primary treatment option Methicillin-Resistant Staphylococcus aureus (MRSA) strains. However, excessive, indiscriminate, or inappropriate use led to appearance of MRSA strains with intermediate resistance (VISA) and total vancomycin (VRSA) 1. In Central America, particularly in Honduras, no VRSA have reported. it is vitally important implement an epidemiological surveillance program where this isolation can be traced since its a severe public health problem last two decades 2. By 2002, first were isolated, specifically Michigan Pennsylvania. Since then, 52 isolates reported worldwide. The only country Latin America that Brazil3. sense, we carried out assay determine MIC 96 clinical S.aureus obtained from patients who attended essential hospital centers Tegucigalpa, Honduras: Hospital Escuela (HE) Honduran Institute Social Security (IHSS). samples same which studied methicillin, follow-up study was previously published journal4. S. determined using E-test® strips (Solna, Sweden) under conditions previous study4 based on what recommended by CLSI5 (figure 1). cohort points susceptibility S.aures seen Table